Pluri (PLUR) AI Stock Analysis

• Market Cap: $45.35M
• Dividend Yield: N/A
• Average Volume (3M): 44.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 203.23%
• EPS Growth: 13.57%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 7,832,601
• 10 Day Avg. Volume: 63,860
• 30 Day Avg. Volume: 44,195
• PEG Ratio: -0.13
• Price to Book (P/B): 3.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.45
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: 26.05
• Enterprise Value/Gross Profit: 143.64
• Enterprise Value/Ebitda: -0.85
• 1Y Price Target: $8.00
• Price Target Upside: 45.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: $6.00 ▲(8.89%Upside)

Pluri's overall stock score reflects significant financial challenges, with high leverage and negative cash flow being primary concerns. The mixed technical indicators suggest some bullish momentum, but caution is advised due to potential overbought conditions. The negative P/E ratio indicates a lack of profitability, impacting valuation negatively. The recent corporate event of regaining Nasdaq compliance is a positive, but financial and profitability issues remain the most significant factors.

Pluri Business Overview & Revenue Model

Company Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

How the Company Makes Money

Pluri generates revenue through multiple streams, primarily by developing and commercializing its proprietary cell-based products and therapies. The company monetizes its innovations through partnerships and collaborations with pharmaceutical and biotechnology firms, which may involve licensing agreements, joint ventures, or co-development deals. These partnerships often provide Pluri with upfront payments, milestone payments, and royalties based on the sales of co-developed products. Additionally, Pluri may receive funding from grants and government contracts aimed at supporting research initiatives. The company's financial performance is influenced by its ability to successfully bring products to market, secure strategic partnerships, and achieve regulatory approvals for its therapies.

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges across its income statement, balance sheet, and cash flow. The company struggles with profitability, high leverage, and negative cash flow, posing substantial risks to financial stability.

Income Statement

Pluri's income statement reveals persistent challenges, characterized by negative EBIT and EBITDA margins, indicating substantial operational losses. The gross profit margin is exceptionally high in TTM (Trailing-Twelve-Months), but this is offset by significant net losses, resulting in a negative net profit margin. Revenue growth is inconsistent, with occasional increases, but overall revenue remains minimal compared to industry standards.

Balance Sheet

The balance sheet highlights financial instability, with a negative stockholders' equity indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, suggesting high leverage and financial risk. The company's equity ratio is unfavorably negative, indicative of a weak financial foundation.

Cash Flow

Cash flow statements show negative free cash flow and operating cash flow, reflecting cash outflows exceeding inflows. The free cash flow to net income ratio is unfavorable, and the operating cash flow to net income ratio is also negative, indicating cash flow issues. Despite efforts to raise financing, the cash flow situation remains challenging.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	1.03M	326.00K	287.00K	234.00K	0.00	23.00K
Gross Profit	478.00K	322.00K	278.00K	-41.36M	-50.62M	-1.55M
EBITDA	-19.76M	-20.23M	-27.68M	-39.43M	-48.42M	-27.91M
Net Income	-20.90M	-20.89M	-28.32M	-41.02M	-49.87M	-29.35M
Balance Sheet
Total Assets	0.00	39.53M	50.80M	68.06M	93.54M	65.53M
Cash, Cash Equivalents and Short-Term Investments	0.00	30.24M	40.17M	55.02M	64.95M	45.78M
Total Debt	6.24M	29.61M	29.91M	28.80M	24.58M	1.58M
Total Liabilities	31.22M	34.11M	35.50M	35.88M	36.39M	9.43M
Stockholders Equity	-4.47M	96.00K	13.36M	30.04M	57.15M	56.10M
Cash Flow
Free Cash Flow	-18.21M	-18.34M	-23.12M	-36.78M	-31.28M	-26.64M
Operating Cash Flow	-17.31M	-18.02M	-22.86M	-36.50M	-30.91M	-26.37M
Investing Cash Flow	193.00K	10.58M	9.70M	11.78M	-7.26M	-30.46M
Financing Cash Flow	18.81M	8.84M	8.02M	7.50M	61.40M	60.87M

Pluri Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 5.51 is above the 20-day moving average (MA) of 4.83, above the 50-day MA of 4.82, and above the 200-day MA of 4.74, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 60.30 is Neutral, neither overbought nor oversold. The STOCH value of 78.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.49B	0.22	-61.87%	2.28%	16.62%	1.08%
PLUR	50 Neutral	$45.35M	―	-1205.58%	―	203.23%	13.57%
CLNN	48 Neutral	$34.76M	―	-1738.36%	―	-43.55%	69.81%
GDTC	41 Neutral	$27.20M	―	-24.97%	―	―	38.80%
DARE	40 Underperform	$21.24M	―	597.53%	―	88.13%	92.45%
TPST	39 Underperform	$28.94M	―	-282.07%	―	―	-220.54%
NRSN	30 Underperform	$50.14M	―	-2880.11%	―	―	31.09%

Pluri Corporate Events

Pluri’s 2025 Annual Meeting Decisions Announced

On June 30, 2025, Pluri held its 2025 Annual Meeting where shareholders voted on several proposals. Key decisions included the election of directors, ratification of the accounting firm Kesselman & Kesselman, approval of the 2016 Equity Compensation Plan, and the determination that future advisory votes on executive compensation will occur every two years. Additionally, the approval of the exercise of warrants related to a private placement offering was confirmed, excluding shares owned by Mr. Alexandre Weinstein.

The most recent analyst rating on (PLUR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Pluri Regains Nasdaq Compliance Before Deadline

Pluri Inc. received a deficiency letter from Nasdaq on November 25, 2024, for not meeting the stockholders’ equity requirement or alternative listing standards. After submitting a compliance plan, Nasdaq granted an extension until May 24, 2025. By May 7, 2025, Pluri regained compliance by maintaining a market value of $35 million for 10 consecutive days, ensuring its continued listing on The Nasdaq Capital Market.